| scholarly article | Q13442814 |
| P50 | author | Karine Lacombe | Q60732323 |
| Anders Boyd | Q88372332 | ||
| Lawrence Serfaty | Q92956715 | ||
| Pierre-Marie Girard | Q96759967 | ||
| Julie Bottero | Q114532498 | ||
| Patrick Miailhes | Q114532499 | ||
| Hayette Rougier | Q114532501 | ||
| Caroline Lascoux-Combe | Q47006613 | ||
| P2860 | cites work | Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B | Q82822290 |
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | Q34317204 | ||
| Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection | Q34606036 | ||
| Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. | Q35155090 | ||
| Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy | Q35588143 | ||
| Review of atazanavir: a novel HIV protease inhibitor | Q36222006 | ||
| Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection | Q36461601 | ||
| Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy | Q36708245 | ||
| Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load | Q37346823 | ||
| From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging | Q37447269 | ||
| Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. | Q37462557 | ||
| The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. | Q37476498 | ||
| Natural history of chronic hepatitis B in Euro-Mediterranean and African countries | Q37828960 | ||
| Noninvasive methods to assess liver disease in patients with hepatitis B or C. | Q38005794 | ||
| Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. | Q38321507 | ||
| Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus | Q38918604 | ||
| Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana | Q39491769 | ||
| Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons | Q40122709 | ||
| Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis | Q42173015 | ||
| Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. | Q42210609 | ||
| Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications | Q42223115 | ||
| Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. | Q42253735 | ||
| No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. | Q42277100 | ||
| Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. | Q42839652 | ||
| Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus | Q42923518 | ||
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. | Q42947269 | ||
| Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus | Q43419593 | ||
| Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression | Q43533077 | ||
| High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients | Q43586321 | ||
| A comparison of fibrosis progression in chronic liver diseases | Q44314885 | ||
| Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir | Q45172156 | ||
| Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease | Q45411408 | ||
| Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis | Q46415674 | ||
| Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. | Q46974815 | ||
| Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin | Q47732710 | ||
| Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. | Q51374916 | ||
| Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. | Q51836061 | ||
| Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs | Q58815702 | ||
| P433 | issue | 1 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| tenofovir | Q155954 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | Journal of the International AIDS Society | Q6296158 |
| P1476 | title | Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study | |
| P478 | volume | 20 |
| Q92933109 | Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV |
| Q89899473 | Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy |
| Q33797424 | Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes |
| Q61443454 | Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression |
| Q92157429 | Liver Fibrosis Conventional and Molecular Imaging Diagnosis Update |
| Q91862651 | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
Search more.